<DOC>
	<DOCNO>NCT01589367</DOCNO>
	<brief_summary>Preoperative letrozole versus letrozole metformin postmenopausal Estrogen receptor positive breast cancer patient Phase II multicenter 1:1 randomized clinical trial Total 208 patient Primary endpoint Clinical response rate Secondary endpoint Pathologic complete response rate Breast conserving surgery rate Percent mammographic density change Ki67 ( % ) change 4week medication 2nd core needle biopsy Toxicity profile neoadjuvant letrozole , metformin</brief_summary>
	<brief_title>Neoadjuvant Letrozole Plus Metformin v Letrozole Plus Placebo ER-positive Postmenopausal Breast Cancer</brief_title>
	<detailed_description>To identify anti-tumor effect metformin preoperatively give letrozole postmenopausal estrogen receptor positive breast cancer patient</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Estrogen receptor positive breast cancer Clinically measurable tumor size ( stage II/III ) No evidence distant metastasis Postmenopause woman 'Age≥60yr ' OR 'previous bilateral oophorectomy ' OR 'FSH &gt; 30 bleed history within 1yr ' ECOG 02 Adequate hepatorenal , bone marrow function 'serum Cr &lt; 1.4mg/dL ' AND 'Bilirubin &lt; upper limit normal x 1.5 AND 'AST/ALT &lt; upper limit normal x 1.8 AND 'ALP &lt; upper limit normal x 1.8 AND 'Hemoglobin &gt; 10 g/dL ' AND 'ANC &gt; 1,500/mm3 ' AND 'Platelet &gt; 100,000/mm3 ' Spontaneous sign write informed consent Who meet inclusion criterion History carcinoma Uncontrolled infection History psychiatric , epileptic disease Male breast cancer Diabetes 'HbA1c≥6.5 ' OR 'FBS≥126mg/dL ' Hypersensitivity intolerance metformin Risk metformin associate lactic acidosis 'Congestive heart disease NYHA Class llll/IV ' OR 'History acidosis ' OR 'Alcohol intake either 3 bottle beer OR 1 bottle Soju ' During medication metformin , sulfonylurea , thiazolidinediones , insulin Diffuse microcalcification mammogram Multiple OR bilateral OR inflammatory breast cancer Chemotherapy endocrine therapy within 2yr due history breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>neoadjuvant endocrine therapy</keyword>
	<keyword>metformin</keyword>
	<keyword>postmenopausal breast cancer</keyword>
</DOC>